Creative Planning’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-1,603
Closed -$99K 2030
2018
Q3
$99K Buy
+1,603
New +$242K ﹤0.01% 1793
2017
Q2
Sell
-1,603
Closed -$1K 4730
2017
Q1
$1K Buy
+1,603
New +$105K ﹤0.01% 4460

Other funds holding LGND

Creative Planning's LGND Position: Q1 2026 in Review

Creative Planning increased its Ligand Pharmaceuticals (LGND) stake by 19% in Q1 2026, buying an estimated $269K and bringing the position to 8,505 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2035.

Creative Planning first reported a position in LGND in Q2 2013 and has held it in 34 quarters since. The position peaked at $3.13M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Creative Planning held 8,505 shares of Ligand Pharmaceuticals worth $1.7M as of Q1 2026.
  • Creative Planning bought 1,360 Ligand Pharmaceuticals shares in Q1 2026, an estimated $269K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #2035 holding.
  • Creative Planning first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
  • Creative Planning's Ligand Pharmaceuticals position peaked at $3.13M in Q3 2018.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.